<DOC>
	<DOCNO>NCT00814034</DOCNO>
	<brief_summary>The objective study monitor change blood coagulation parameter postmenopausal patient treat adjuvant Hormonal Therapy total 5 year . The value standard coagulation parameter throughout study compare baseline value .</brief_summary>
	<brief_title>Coagulation Parameters Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy</brief_title>
	<detailed_description>Study subject treat standard adjuvant hormonal therapy total 5 year disease relapse HT permanently discontinue reason . The choice endocrine treatment strategy ( drug use sequence , sequential option decide ) leave discretion participate site . Adjuvant HT commence completion adjuvant chemotherapy and/or radiotherapy . Percentage change ( % ) baseline blood coagulation parameter 6 , 12 , 18 , 24 month treatment . The blood coagulation parameter measure fibrinogen , prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal status . ER and/or PgR status positive . Adjuvant hormonal treatment 5 year accord standard practice decide treat physician . Values within normal limit blood coagulation parameter baseline visit . Accessible followup duration trial . Written informed consent . Both ER PgR negative primary tumor . Evidence distant metastasis ( M1 ) Neoadjuvant hormonotherapy . Chronic use oral anticoagulant warfarin acenocoumarol . Psychiatric disorder prevent proper inform consent . Concomitant malignancy except adequately treat carcinoma situ uterine cervix basal squamous cell carcinoma skin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Aromatase Inhibitors</keyword>
	<keyword>Coagulation parameter</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>